` RCUS (Arcus Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

RCUS
vs
S&P 500

Over the past 12 months, RCUS has underperformed S&P 500, delivering a return of -48% compared to the S&P 500's 9% growth.

Stocks Performance
RCUS vs S&P 500

Loading
RCUS
S&P 500
Add Stock

Performance Gap
RCUS vs S&P 500

Loading
RCUS
S&P 500
Difference
www.alphaspread.com

Performance By Year
RCUS vs S&P 500

Loading
RCUS
S&P 500
Add Stock

Competitors Performance
Arcus Biosciences Inc vs Peers

S&P 500
RCUS
ABBV
AMGN
GILD
VRTX
Add Stock

Arcus Biosciences Inc
Glance View

Market Cap
902.1m USD
Industry
Biotechnology

Arcus Biosciences Inc., founded in 2015 and based in California, emerges not just as a company, but as a dynamic player in the biopharmaceutical arena with a fervent focus on innovative cancer therapies. The company's narrative is centered around harnessing the power of immunotherapy to combat cancer, a testament to its commitment to push the frontiers of medicine. At the core of Arcus's strategy is its proprietary pipeline of novel molecules designed to promote antitumor immune responses, particularly small-molecule drugs and antibodies. By marrying cutting-edge science with practical clinical applications, Arcus aims to provide treatments that enhance the body's immune response against cancer, offering hope to patients and healthcare providers alike. As Arcus Biosciences spins its operational wheel, its financial engine is fueled primarily through strategic partnerships and licensing agreements. The company collaborates with major pharmaceutical players to co-develop and commercialize its promising candidates, allowing it to share the risks and rewards inherent in drug development. These partnerships not only provide upfront payments and milestone-based financial inflows but also broaden the scope of clinical trials and expedite the pathway to market availability. By aligning their interests with larger entities invested in cutting-edge oncology solutions, Arcus is positioned to capitalize on the symbiotic relationship between innovative early-stage science and the expansive reach of established pharmaceutical channels, striving to bring transformative therapies to the global market.

RCUS Intrinsic Value
11.27 USD
Undervaluation 24%
Intrinsic Value
Price
Back to Top